Tin tức & Cập nhật
Xem bài viết Đa khoa
Xem
Chỉ hiển thị Multimedia

Belzutifan 120 mg on par with higher dose in advanced clear cell RCC
13 Dec 2024
Use of belzutifan, a first-in-class hypoxia-inducible factor subunit 2α (HIF-2α) inhibitor, in patients with advanced clear cell renal cell carcinoma (RCC) is effective in either the 120- or the 200-mg dose, a phase II study has shown. Both doses are also safe.
13 Dec 2024

Osimertinib reduces risk of metastasis, CNS progression in NSCLC
13 Dec 2024
bởiStephen Padilla
Treatment with osimertinib following chemoradiotherapy (CRT) helps lower the risk of distant metastases and central nervous system (CNS) disease progression in patients with unresectable stage III epidermal growth factor receptor-mutated (EGFRm) nonsmall cell lung cancer (NSCLC), results of the phase III LAURA study have shown.
13 Dec 2024







